FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381851537> ?p ?o ?g. }

• W4381851537 endingPage "361" @default.
• W4381851537 startingPage "352" @default.
• W4381851537 abstract "Objective The primary objectives of this scoping review were to assess the rate of and risk factors for type Ib endoleak and to evaluate the extent of the evidence base that links type Ib endoleak to short and long term outcomes in patients undergoing endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA). Methods Potentially eligible studies were searched in the Cochrane Central Register of Controlled Trials, MEDLINE, Web of Science Core Collection, SciELO Citation Index, Russian Science Citation Index, and KCI-Korean Journal Database. A scoping review was performed according to PRISMA extension for Scoping Reviews. Results A total of 27 articles (four prospective registries and 23 retrospective cohort studies) dealing with type Ib endoleak were included in the final analysis. The number of patients reported on was 7 197, with follow up ranging between 12 months and 93 months. The reported frequency of type Ib endoleak in patients treated with EVAR ranged from 0% to 8%, Patient and or procedure related factors associated with risk of type Ib endoleak were (1) common iliac artery (CIA) diameter ˃ 18 mm requiring use of flared stent graft limbs (FLs) ˃ 20 mm, (2) length of CIA landing zone ˂ 20 mm, (3) marked iliac tortuosity, and (4) large initial AAA diameter. Depending on the study, 50 – 100% of type Ib endoleaks were corrected by endovascular means, with a reported immediate technical success of 100% in the studies providing this information. Conclusion Type Ib endoleak after EVAR has been reported to occur in 0 – 8% of cases. Several anatomical features, including CIA diameter ˃ 18 mm or requiring the use of FLs ˃ 20 mm, length of CIA landing zone ˂ 20 mm, marked iliac tortuosity, and large initial AAA diameter, could increase the risk of type Ib endoleak and may require alternative therapeutic options and or more stringent follow up. Therefore, this updated scoping review provides a comprehensive summary of the frequency, risk factors, prognosis, and treatment of type Ib endoleaks, and has identified knowledge gaps in the literature to guide further studies. The primary objectives of this scoping review were to assess the rate of and risk factors for type Ib endoleak and to evaluate the extent of the evidence base that links type Ib endoleak to short and long term outcomes in patients undergoing endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA). Potentially eligible studies were searched in the Cochrane Central Register of Controlled Trials, MEDLINE, Web of Science Core Collection, SciELO Citation Index, Russian Science Citation Index, and KCI-Korean Journal Database. A scoping review was performed according to PRISMA extension for Scoping Reviews. A total of 27 articles (four prospective registries and 23 retrospective cohort studies) dealing with type Ib endoleak were included in the final analysis. The number of patients reported on was 7 197, with follow up ranging between 12 months and 93 months. The reported frequency of type Ib endoleak in patients treated with EVAR ranged from 0% to 8%, Patient and or procedure related factors associated with risk of type Ib endoleak were (1) common iliac artery (CIA) diameter ˃ 18 mm requiring use of flared stent graft limbs (FLs) ˃ 20 mm, (2) length of CIA landing zone ˂ 20 mm, (3) marked iliac tortuosity, and (4) large initial AAA diameter. Depending on the study, 50 – 100% of type Ib endoleaks were corrected by endovascular means, with a reported immediate technical success of 100% in the studies providing this information. Type Ib endoleak after EVAR has been reported to occur in 0 – 8% of cases. Several anatomical features, including CIA diameter ˃ 18 mm or requiring the use of FLs ˃ 20 mm, length of CIA landing zone ˂ 20 mm, marked iliac tortuosity, and large initial AAA diameter, could increase the risk of type Ib endoleak and may require alternative therapeutic options and or more stringent follow up. Therefore, this updated scoping review provides a comprehensive summary of the frequency, risk factors, prognosis, and treatment of type Ib endoleaks, and has identified knowledge gaps in the literature to guide further studies." @default.
• W4381851537 created "2023-06-25" @default.
• W4381851537 creator A5017879678 @default.
• W4381851537 creator A5029419578 @default.
• W4381851537 creator A5030637679 @default.
• W4381851537 creator A5031833848 @default.
• W4381851537 creator A5034758583 @default.
• W4381851537 creator A5038712366 @default.
• W4381851537 creator A5046156442 @default.
• W4381851537 creator A5054836912 @default.
• W4381851537 creator A5067657646 @default.
• W4381851537 creator A5069303195 @default.
• W4381851537 creator A5082032866 @default.
• W4381851537 date "2023-09-01" @default.
• W4381851537 modified "2023-10-16" @default.
• W4381851537 title "Incidence, Risk Factors, and Prognostic Impact of Type Ib Endoleak Following Endovascular Repair for Abdominal Aortic Aneurysm: Scoping Review" @default.
• W4381851537 cites W1841268800 @default.
• W4381851537 cites W1964044430 @default.
• W4381851537 cites W1969170591 @default.
• W4381851537 cites W1992645384 @default.
• W4381851537 cites W2012332577 @default.
• W4381851537 cites W2017981408 @default.
• W4381851537 cites W2052291433 @default.
• W4381851537 cites W2055891585 @default.
• W4381851537 cites W2100850234 @default.
• W4381851537 cites W2113118274 @default.
• W4381851537 cites W2118556563 @default.
• W4381851537 cites W2124146726 @default.
• W4381851537 cites W2153972853 @default.
• W4381851537 cites W2284133718 @default.
• W4381851537 cites W2551727447 @default.
• W4381851537 cites W2567131111 @default.
• W4381851537 cites W2591942255 @default.
• W4381851537 cites W2727081472 @default.
• W4381851537 cites W2773974849 @default.
• W4381851537 cites W2807647870 @default.
• W4381851537 cites W2891378911 @default.
• W4381851537 cites W2902783010 @default.
• W4381851537 cites W2906650493 @default.
• W4381851537 cites W2912179418 @default.
• W4381851537 cites W2918977207 @default.
• W4381851537 cites W2921583770 @default.
• W4381851537 cites W2947581587 @default.
• W4381851537 cites W2947955762 @default.
• W4381851537 cites W2965615278 @default.
• W4381851537 cites W2966393539 @default.
• W4381851537 cites W2969534431 @default.
• W4381851537 cites W2999255530 @default.
• W4381851537 cites W2999939077 @default.
• W4381851537 cites W3011927227 @default.
• W4381851537 cites W3023479020 @default.
• W4381851537 cites W3037104672 @default.
• W4381851537 cites W3044949604 @default.
• W4381851537 cites W3083726738 @default.
• W4381851537 cites W3085514753 @default.
• W4381851537 cites W3107974203 @default.
• W4381851537 cites W3126757525 @default.
• W4381851537 cites W3143805473 @default.
• W4381851537 cites W3183439546 @default.
• W4381851537 cites W4220778211 @default.
• W4381851537 cites W4283794130 @default.
• W4381851537 doi "https://doi.org/10.1016/j.ejvs.2023.06.017" @default.
• W4381851537 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37356703" @default.
• W4381851537 hasPublicationYear "2023" @default.
• W4381851537 type Work @default.
• W4381851537 citedByCount "1" @default.
• W4381851537 countsByYear W43818515372023 @default.
• W4381851537 crossrefType "journal-article" @default.
• W4381851537 hasAuthorship W4381851537A5017879678 @default.
• W4381851537 hasAuthorship W4381851537A5029419578 @default.
• W4381851537 hasAuthorship W4381851537A5030637679 @default.
• W4381851537 hasAuthorship W4381851537A5031833848 @default.
• W4381851537 hasAuthorship W4381851537A5034758583 @default.
• W4381851537 hasAuthorship W4381851537A5038712366 @default.
• W4381851537 hasAuthorship W4381851537A5046156442 @default.
• W4381851537 hasAuthorship W4381851537A5054836912 @default.
• W4381851537 hasAuthorship W4381851537A5067657646 @default.
• W4381851537 hasAuthorship W4381851537A5069303195 @default.
• W4381851537 hasAuthorship W4381851537A5082032866 @default.
• W4381851537 hasConcept C120665830 @default.
• W4381851537 hasConcept C121332964 @default.
• W4381851537 hasConcept C126838900 @default.
• W4381851537 hasConcept C141071460 @default.
• W4381851537 hasConcept C167135981 @default.
• W4381851537 hasConcept C2776098176 @default.
• W4381851537 hasConcept C2776543907 @default.
• W4381851537 hasConcept C2777323849 @default.
• W4381851537 hasConcept C2778583881 @default.
• W4381851537 hasConcept C2779993416 @default.
• W4381851537 hasConcept C61511704 @default.
• W4381851537 hasConcept C71924100 @default.
• W4381851537 hasConceptScore W4381851537C120665830 @default.
• W4381851537 hasConceptScore W4381851537C121332964 @default.
• W4381851537 hasConceptScore W4381851537C126838900 @default.
• W4381851537 hasConceptScore W4381851537C141071460 @default.
• W4381851537 hasConceptScore W4381851537C167135981 @default.
• W4381851537 hasConceptScore W4381851537C2776098176 @default.
• W4381851537 hasConceptScore W4381851537C2776543907 @default.

• next